Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer.
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer.
复制标题
肿瘤微环境中的髓样细胞特征预测癌症的治疗反应。
DOI：
10.2147/ott.s102907
复制
发表时间：
2016
影响因子：
4
通讯作者：
Arbab AS
中科院分区：
文献类型：
--
作者：
Achyut BR;Arbab AS
肿瘤微环境（TME）由包括肿瘤细胞在内的多种免疫和非免疫细胞群组成。几十年来，实验研究已经描绘了TME对癌症进展和转移发展的深刻贡献。已经通过临床前研究和临床试验测试了几种针对TME的治疗策略。不幸的是，它们中的大多数已经显示出短暂的效果，并且由于侵袭性肿瘤生长而在很大程度上失败，并且没有改善存活率。已知实体瘤在肿瘤发展中具有强骨髓成分（例如，肿瘤相关巨噬细胞）。最近的数据表明，肿瘤的治疗反应的特征在于免疫细胞特征的改变，包括肿瘤相关的骨髓细胞。极化的肿瘤相关骨髓细胞（M1-M2）在损害治疗效果和促进肿瘤生长方面至关重要。本综述旨在收集所有与不同髓系细胞群体在肿瘤发展和治疗失败中的作用相关的文献。最后，我们讨论了髓系细胞群体作为化疗、靶向治疗或放射治疗的联合治疗的靶向。
Tumor microenvironment (TME) consists of several immune and nonimmune cell populations including tumor cells. For many decades, experimental studies have depicted profound contribution of TME toward cancer progression and metastasis development. Several therapeutic strategies have been tested against TME through preclinical studies and clinical trials. Unfortunately, most of them have shown transient effect, and have largely failed due to aggressive tumor growth and without improving survival. Solid tumors are known to have a strong myeloid component (eg, tumor-associated macrophages) in tumor development. Recent data suggest that therapeutic responses in tumor are characterized by alterations in immune cell signatures, including tumor-associated myeloid cells. Polarized tumor-associated myeloid cells (M1–M2) are critical in impairing therapeutic effect and promoting tumor growth. The present review is intended to compile all the literatures related to the emerging contribution of different populations of myeloid cells in the development of tumor and therapeutic failures. Finally, we have discussed targeting of myeloid cell populations as a combination therapy with chemo-, targeted-, or radiation therapies.